Brett A. Lovejoy, Ph.D.

Partner

Brett A. Lovejoy, Ph.D., is a partner in Morgan Lewis's Intellectual Property Practice. Dr. Lovejoy's practice includes patent counseling, prosecution, opinions, licensing, IP litigation support, transactional due diligence, and trademarks. He counsels clients in connection with intellectual property portfolio development and enforcement, including analysis of infringement, noninfringement, and invalidity of patents.

Dr. Lovejoy has written and prosecuted thousands of patents involving a wide range of technologies, including computer-implemented technology, software, renewable energy, diagnostics, medical devices, chemistry, biochemistry, bioinformatics, semiconductor processing, electrical circuit design, high fashion, and novelty products.

Prior to joining Morgan Lewis, Dr. Lovejoy was a partner in the Intellectual Property Practice of an international law firm.

Dr. Lovejoy began his legal career in 1998 as a patent agent and has achieved a high level of proficiency in prosecuting software patent applications since then. He has written hundreds of software patent applications, many of which have issued. Many patent applications written by Dr. Lovejoy have been sold to third parties or enforced successfully through litigation. Prior to his legal career, Dr. Lovejoy authored many software programs in several different programming languages as part of his work as a post-doctoral fellow at UCLA, and as a research scientist at GlaxoSmithKline and Roche.

Dr. Lovejoy is a first author of numerous peer-reviewed articles, including a Science article describing the X-ray crystal structure of a GlaxoSmithKline inhibitor bound to the active site of collagenase, and a Science report describing the X-ray crystal structure of a synthetic designer protein developed in a collaboration between David Eisenberg of UCLA and DuPont.

Dr. Lovejoy is admitted to practice in California and before the U.S. Patent and Trademark Office.